All In Biotech

Drug Trial Radar · NCT06220318

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

A Phase I/II Clinical Study on the Safety, Tolerability and Preliminary Efficacy of C019199 in Combination With Sintilimab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

155

Planned (sponsor's estimate)

Start

Jul 19, 2023

Primary completion

Aug 30, 2026

Study completion Aug 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.

Conditions

  • Solid Tumor

Interventions

  • C019199Drug

    The C019199 will be taken orally, once a day

  • SintilimabDrug

    Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT)Time frame: Cycle 1 (Cycle length=21 days)
  2. Objective Response Rate (ORR) Based on iRECISTTime frame: From date of enrollment until the date of first documented progression or death
  3. Progression-free Survival (PFS) after administrationTime frame: From date of enrollment until the date of first documented progression or death

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.